全文获取类型
收费全文 | 99540篇 |
免费 | 7170篇 |
国内免费 | 321篇 |
专业分类
耳鼻咽喉 | 1274篇 |
儿科学 | 2535篇 |
妇产科学 | 2310篇 |
基础医学 | 12445篇 |
口腔科学 | 2062篇 |
临床医学 | 9727篇 |
内科学 | 21726篇 |
皮肤病学 | 1069篇 |
神经病学 | 8655篇 |
特种医学 | 3359篇 |
外国民族医学 | 3篇 |
外科学 | 16239篇 |
综合类 | 1403篇 |
现状与发展 | 1篇 |
一般理论 | 75篇 |
预防医学 | 7870篇 |
眼科学 | 2655篇 |
药学 | 6346篇 |
中国医学 | 142篇 |
肿瘤学 | 7135篇 |
出版年
2023年 | 363篇 |
2022年 | 587篇 |
2021年 | 1645篇 |
2020年 | 880篇 |
2019年 | 1586篇 |
2018年 | 1903篇 |
2017年 | 1399篇 |
2016年 | 1552篇 |
2015年 | 1834篇 |
2014年 | 2726篇 |
2013年 | 4318篇 |
2012年 | 6185篇 |
2011年 | 6454篇 |
2010年 | 3618篇 |
2009年 | 3343篇 |
2008年 | 6124篇 |
2007年 | 6817篇 |
2006年 | 6517篇 |
2005年 | 6662篇 |
2004年 | 6498篇 |
2003年 | 6115篇 |
2002年 | 6108篇 |
2001年 | 788篇 |
2000年 | 541篇 |
1999年 | 771篇 |
1998年 | 1283篇 |
1997年 | 1139篇 |
1996年 | 965篇 |
1995年 | 972篇 |
1994年 | 853篇 |
1993年 | 744篇 |
1992年 | 567篇 |
1991年 | 514篇 |
1990年 | 450篇 |
1989年 | 467篇 |
1988年 | 439篇 |
1987年 | 455篇 |
1986年 | 450篇 |
1985年 | 513篇 |
1984年 | 716篇 |
1983年 | 757篇 |
1982年 | 978篇 |
1981年 | 917篇 |
1980年 | 868篇 |
1979年 | 449篇 |
1978年 | 532篇 |
1977年 | 581篇 |
1976年 | 491篇 |
1975年 | 429篇 |
1974年 | 341篇 |
排序方式: 共有10000条查询结果,搜索用时 359 毫秒
71.
Thomas G. Hardy Jr. M.D. Pedro S. Aguilar M.D. Dr. William R. C. Stewart M.D. 《Diseases of the colon and rectum》1989,32(6):528-532
Three patients with complete colonic obstruction treated by primary resection and anastomosis with intraoperative colon tube decompression and bowel lumen sterilization without a protective colostomy are presented. An improved colonic decompressor was used. It is postulated that this procedure is an alternative safe technique in patients with colonic obstruction in whom an end-colostomy, mucous fistula, or Hartmann pouch would be necessary. 相似文献
72.
73.
74.
Prostatitis accounts for almost 2 million office visits to urologists and primary care physicians. The label “prostatitis” refers to a diverse constellation of symptoms and disease processes. The diagnosis and treatment of this disorder present numerous challenges for the physician, including a lack of abnormal findings on physical examination, laboratory tests, and radiographic images. In this article, we offer a review of the current literature and recommendations for the evaluation and diagnosis of the patient presenting with prostatitis. 相似文献
75.
Alcides José Branco Filho William Kondo Luis Sérgio Nassif Mariana Jorge Garcia Rafael de Almeida Tirapelle Carlos Marcelo Dotti 《JSLS, Journal of the Society of Laparoendoscopic Surgeons》2006,10(3):326-331
BACKGROUND: Gastrogastric fistula is a communication between the proximal gastric pouch and the distal gastric remnant, rarely described in the realm of bariatric procedures. The aim of this study was to review the existing literature about this topic and to demonstrate its laparoscopic treatment. METHODS: An extensive literature review found several articles reporting this complication. However, no citation was found describing the steps of the laparoscopic management of this situation. RESULTS: Gastrogastric fistula occurs in up to 6% of Roux-en-Y gastric bypasses. Two theories exist for fistula formation: (1) it is a technical complication derived from the incomplete division of the stomach during the creation of the pouch, and (2) it occurs after a staple-line failure, developing a leak with an abscess, which then drains into the distal stomach forming the fistula. Early symptoms include fever, tachycardia, and abdominal pain. Failure in weight loss is a late clinical sign observed in these patients. Diagnosis is based on radiologic study, upper endoscopy and computed tomography. When identified in the acute postoperative course, laparoscopic treatment is easy. Chronic fistulas are difficult to manage, and the laparoscopic approach is an alternative to open surgery. CONCLUSIONS: Gastrogastric fistula is a possible complication of Roux-en-Y gastric bypass and its laparoscopic treatment is feasible. 相似文献
76.
77.
Hua Tan Jena Derrick Jin Hong Corneliu Sanda William M Grosse Howard J Edenberg Milton Taylor Scott Seiwert Lawrence M Blatt 《Journal of interferon & cytokine research》2005,25(10):632-649
A role for type II interferon (IFN-gamma) in resolving viral infection is suggested by the correlation of hepatitis C virus (HCV) clearance with enhancement of IFN-gamma-producing activated T cells in the resolution of acute HCV infection. Using vesicular stomatitis virus (VSV), a synergistic direct antiviral effect was documented using IFN-gamma1b and a potent, consensus type I IFN (IFN alfacon-1). Global expression profiling following EC50 exposure to IFN alfacon-1, IFN-gamma1b, or a cocktail of the two allowed the antiviral state to be correlated with induction of a subset of IFN-stimulated genes (ISGs). Genes identified through this analysis corresponded to classic antiviral components, ISGs more recently associated with direct antiviral functions, as well as expressed sequence tags (ESTs) and hypothetical proteins. The magnitude of these antiviral EC50-correlated expression events in human hepatoma (Huh7) cells exposed to clinically relevant doses of IFN alfacon-1, IFN-gamma1b, or a cocktail of the two was also probed because the standard of care for patients with chronic hepatitis C is type I IFN-containing regimens. Relative to type I IFNs used alone, the addition of type II IFN caused enhanced expression not only of many of the genes correlated with the direct antiviral state but also of genes involved in (1) antigen presentation to cytotoxic T lymphocytes (CTLs), (2) macrophage, natural killer (NK), and T helper 1 (Th1) cell recruitment and activation, (3) complement system function, (4) apoptosis, and (5) ISGs with unknown functions. As many of these processes are correlated clinically with resolution of chronic HCV infection, the combined use of these IFNs could display a beneficial effect on viral clearance in patients infected with HCV and other viruses through enhancement of one of these processes or of the direct antiviral state. 相似文献
78.
Practical management of patients with non-small-cell lung cancer treated with gefitinib. 总被引:7,自引:0,他引:7
Neelam T Shah Mark G Kris William Pao Leslie B Tyson Barbara M Pizzo Murk-Hein Heinemann Leah Ben-Porat Dana L Sachs Robert T Heelan Vincent A Miller 《Journal of clinical oncology》2005,23(1):165-174
PURPOSE: The use of gefitinib, the first drug approved to inhibit the epidermal growth factor receptor tyrosine kinase, is indicated in patients with non-small-cell lung cancer with tumors progressive after chemotherapy. The unique mechanism of action of this agent leads to distinctive patterns of response and toxicity in persons with lung cancer. Many of the principles of management relevant to gefitinib are distinct from those with conventional cytotoxic drugs. To meet this need, we present practical guidelines on the use of gefitinib in patients with non-small-cell lung cancer. METHODS: This article reviews gefitinib's indications, dosing, response phenomena, and patterns of relapse in individuals with radiographic response. RESULTS: We present our recommendations for the management of rash and diarrhea caused by this agent. CONCLUSION: This information can guide practitioners and help them inform their patients about what to expect when they receive gefitinib. 相似文献
79.
80.